Navigation Links
NUS study shows effectiveness of common anti-malarial drug in controlling asthma

Asthmatic patients may soon have a more effective way to control the condition, thanks to a new pharmacological discovery by researchers from the National University of Singapore (NUS).

The team, led by Associate Professor Fred Wong from the Department of Pharmacology at the NUS Yong Loo Lin School of Medicine, together with Dr Eugene Ho Wanxing, a recent PhD graduate from the Saw Swee Hock School of Public Health at NUS, discovered that artesunate, a common herbal-based anti-malarial drug, can be used to control asthma, with better treatment outcomes than other drugs currently available.

In their latest work, the team revealed for the first time that artesunate is able to suppress airway inflammation and produce an array of anti-inflammatory effects similar to those by dexamethasone, the most potent steroid currently available, and with less side effects. This breakthrough discovery was first published in the journal Metabolomics on 16 July 2014.

Earlier this year, the NUS team was invited by renowned journal Pharmacology and Therapeutics to pen a comprehensive review of the pharmacological effects of artesunate, and the review article was published in the journal in April 2014.

The quest for better asthma therapeutics

Asthma is an incurable lung disease that inflames and narrows the airways, causing recurring periods of wheezing, chest tightness, coughing and shortness of breath. It is a chronic condition that affects people of all ages, but it most often starts during childhood.

To address the global unmet demand for better therapeutics to control allergic asthma, Dr Ho explored the therapeutic values of artesunate, which is herbal-based, as an alternative drug candidate. This study was part of Dr Ho's final-year project when he was pursuing a Bachelor of Science in Life Sciences at NUS. His initial findings demonstrated that artesunate possessed promising anti-inflammatory potential.

Dr Ho was recognised by the Singapore-MIT Alliance (SMA) in 2010 for his novel discovery, and he was awarded the SMA Graduate Fellowship for his PhD studies at NUS.

For his postgraduate studies, Dr Ho built upon his findings to better understand the therapeutic properties and molecular mechanisms of artesunate under the supervision of Assoc Prof Fred Wong.

The NUS team studied the therapeutic effects of artesunate against oxidative stress and oxidative lung damage which are major inflammatory events that contribute to the severity of asthma attacks. They found that artesunate could better prevent oxidative lung damage, a major molecular inflammatory event in asthmatic lungs, than clinically-used corticosteroid, dexamethasone.

Their collective results revealed that artesunate can be used to better control asthma, with improved outcomes and lesser adverse effects than currently available drugs. As long term usage of steroids may induce many potential side effects in asthmatic patients, the significance of this study suggests that the patients may eventually be able to adopt artesunate as a safer and more effective alternative to control their asthma.

The next step

Moving forward, the team led by Assoc Prof Wong will further explore the therapeutic and pharmacological effects of artesunate for asthma, as well as for other medical conditions. They also intend to work with industry partners to test the effects of artesunate on asthmatic patients.

Dr Ho is also furthering his research as a Research Fellow at the Saw Swee Hock School of Public Health at NUS, where he is investigating the molecular mechanisms of artesunate, and hopes to discover more beneficial effects of artesunate and accelerate the adoption of this drug for clinical tests.


Contact: Carolyn Fong
National University of Singapore

Related biology news :

1. Study of bigeye tuna in Northwest Atlantic uses new tracking methods
2. UF study advances DNA revolution, tells butterflies evolutionary history
3. Study of twins discovers gene mutation linked to short sleep duration
4. Study finds benefits to burning Flint Hills prairie in fall and winter
5. UT Dallas study reveals effect of loud noises on brain
6. New international tree nut council study looks at nuts, diabetes and metabolic syndrome
7. Study: Marine pest provides advances in maritime anti-fouling and biomedicine
8. Healthy lifestyle may buffer against stress-related cell aging, study says
9. Study suggests disruptive effects of anesthesia on brain cell connections are temporary
10. Study finds Europes habitat and wildlife is vulnerable to climate change
11. Dinosaurs fell victim to perfect storm of events, study shows
Post Your Comments:
Related Image:
NUS study shows effectiveness of common anti-malarial drug in controlling asthma
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015  CardioCell LLC, a Stemedica ... cells for cardiovascular indications, intends to proceed with ... on recommendations from a Heart Failure Advisory Board ... Scientific Advisory Board members . In a recent ... IIa safety and efficacy data from CardioCell,s on-going ...
(Date:12/1/2015)... Cepheid (Nasdaq: CPHD ) today announced ... Jaffray Healthcare Conference in New York City ... its outlook for the fourth quarter of 2015 and ... longer term business model expectations. John Bishop ... to be the fastest growing company of the major ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... physicians, aesthetic practitioners and aesthetics professionals from Central America and abroad for the ... in Panama City, Panama Feb. 17-19, 2016. Testart will present and discuss new ...
(Date:11/30/2015)... , Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... it has joined the American Business Act on Climate Pledge, ... that are standing with the Obama Administration to demonstrate an ... a strong outcome to the COP21 Paris ... --> Sarnia, Canada . --> ...
Breaking Biology Technology: